HealthCor Management, L.P.
Follow13F filer, CIK 1343781, NEW YORK, NY
HealthCor Management, L.P. reported $109,111,527 across 22 holdings for the quarter ended 2022-12-31, in a 13F-HR filed 2023-02-15. Its ten largest share positions make up 91.26% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001343781-23-000001
- Period
- 2022-12-31
- Reported value
- $109M
- Holdings
- 22
- Top 10 weight
- 91.26%
- New
- 6
- Sold out
- 43
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| DXCMadded | +67,880 | $7.69M |
| ACRVnew | +284,201 | $3.27M |
| CNMDnew | +27,500 | $2.44M |
| ISRGnew | +5,750 | $1.53M |
| PENnew | +5,000 | $1.11M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ABBVexited | -310,250 | -$41.6M |
| Aexited | -338,030 | -$41.1M |
| BMRNreduced | -391,273 | -$40.5M |
| BSXexited | -958,600 | -$37.1M |
| LLYexited | -103,150 | -$33.4M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2022
Share positions as resolved from 13F-HR 0001343781-23-000001, largest first. % of portfolio is the value over $109,111,523, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| BMRNBIOMARIN PHARMACEUTICAL INC | 367,765 | $38.1M | 34.88% | -391,273 | Timeline | ||
| DXCMDEXCOM INC | 321,380 | $36.4M | 33.35% | +67,880 | Timeline | ||
| CYTKCYTOKINETICS INC | 164,440 | $7.53M | 6.91% | -270,120 | Timeline | ||
| ACRVACRIVON THERAPEUTICS INC | 284,201 | $3.27M | 3% | new | Timeline | ||
| HYPRHYPERFINE INC | 3,880,900 | $3.26M | 2.99% | +1,131,500 | Timeline | ||
| ALKSALKERMES PLC | 110,000 | $2.87M | 2.63% | -193,500 | Timeline | ||
| CNMDCONMED CORP | 27,500 | $2.44M | 2.23% | new | Timeline | ||
| NBIXNEUROCRINE BIOSCIENCES INC | 20,000 | $2.39M | 2.19% | -1,720 | Timeline | ||
| SNDXSYNDAX PHARMACEUTICALS INC | 70,000 | $1.78M | 1.63% | -789,240 | Timeline | ||
| CHINOOK THERAPEUTICS INCCHINOOK THERAPEUTICS INC | 60,000 | $1.57M | 1.44% | -206,830 | |||
| ISRGINTUITIVE SURGICAL INC | 5,750 | $1.53M | 1.4% | new | Timeline | ||
| BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORP | 30,000 | $1.31M | 1.2% | -74,600 | |||
| GERNGERON CORP | 500,000 | $1.21M | 1.11% | -1,404,234 | Timeline | ||
| PENPENUMBRA INC | 5,000 | $1.11M | 1.02% | new | Timeline | ||
| RCKTROCKET PHARMACEUTICALS INC | 50,000 | $978K | 0.9% | -395,140 | Timeline | ||
| RAIN ONCOLOGY INCRAIN ONCOLOGY INC | 120,000 | $960K | 0.88% | new | |||
| INSPINSPIRE MED SYS INC | 3,500 | $882K | 0.81% | -34,740 | Timeline | ||
| SILK ROAD MEDICAL INCSILK ROAD MEDICAL INC | 15,000 | $793K | 0.73% | new | |||
| IMMUNOGEN INCIMMUNOGEN INC | 150,000 | $744K | 0.68% | -1,150,000 | |||
| EQRX INCEQRX INC | 35,239 | $9.45K | 0.01% | 0 | |||
| EUCRATES BIOMEDICAL ACQU COREUCRATES BIOMEDICAL ACQU COR | 78,059 | $4.34K | <0.01% | 0 | |||
| MEDICUS SCIENCES ACQUISITIONMEDICUS SCIENCES ACQUISITION | 29,776 | $2.68K | <0.01% | 0 |
Sold out in Q4 2022
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| ABBVABBVIE INC | 310,250 | $41.6M | shares |
| AAGILENT TECHNOLOGIES INC | 338,030 | $41.1M | shares |
| BSXBOSTON SCIENTIFIC CORP | 958,600 | $37.1M | shares |
| LLYELI LILLY & CO | 103,150 | $33.4M | shares |
| CORCENCORA INC | 239,150 | $32.4M | shares |
| UNHUNITEDHEALTH GROUP INC | 62,980 | $31.8M | shares |
| DHRDANAHER CORP DEL | 117,800 | $30.4M | shares |
| THCTENET HEALTHCARE CORP | 518,990 | $26.8M | shares |
| TMOTHERMO FISHER SCIENTIFIC INC | 51,240 | $26M | shares |
| CNCCENTENE CORP DEL | 300,970 | $23.4M | shares |
| CITHE CIGNA GROUP | 76,910 | $21.3M | shares |
| HUMHUMANA INC | 42,920 | $20.8M | shares |
| BIIBBIOGEN INC | 69,950 | $18.7M | shares |
| ELVELEVANCE HEALTH INC FORMERLY | 38,910 | $17.7M | shares |
| AMGNAMGEN INC | 75,370 | $17M | shares |
| LIVNLIVANOVA PLC | 328,030 | $16.7M | shares |
| HSICSCHEIN HENRY INC | 248,920 | $16.4M | shares |
| BMYBRISTOL-MYERS SQUIBB CO | 223,150 | $15.9M | shares |
| INCYINCYTE CORP | 227,851 | $15.2M | shares |
| HORIZON THERAPEUTICS PLCHORIZON THERAPEUTICS PLC | 229,530 | $14.2M | shares |
| BDXBECTON DICKINSON & CO | 62,930 | $14M | shares |
| KEZAR LIFE SCIENCES INCKEZAR LIFE SCIENCES INC | 1,607,650 | $13.8M | shares |
| CVSCVS HEALTH CORP | 131,150 | $12.5M | shares |
| MCKMCKESSON CORP | 35,040 | $11.9M | shares |
| ABTABBOTT LABORATORIES | 98,970 | $9.58M | shares |
| MOHMOLINA HEALTHCARE INC | 27,540 | $9.08M | shares |
| HOLXHOLOGIC INC | 137,330 | $8.86M | shares |
| SEAGEN INCSEAGEN INC | 57,340 | $7.85M | shares |
| SHOCKWAVE MED INCSHOCKWAVE MED INC | 19,720 | $5.48M | shares |
| MERUS N VMERUS N V | 272,890 | $5.47M | shares |
| XRAYDENTSPLY SIRONA INC | 158,200 | $4.49M | shares |
| AFFIMED N VAFFIMED N V | 1,721,925 | $3.55M | shares |
| CANO HEALTH INCCANO HEALTH INC | 395,560 | $3.43M | shares |
| NEONEOGENOMICS INC | 391,110 | $3.37M | shares |
| NEVRO CORPNEVRO CORP | 67,600 | $3.15M | shares |
| BLUEBIRD BIO INCBLUEBIRD BIO INC | 455,000 | $2.88M | shares |
| NTRANATERA INC | 65,130 | $2.85M | shares |
| REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INC | 64,590 | $1.74M | shares |
| IVERIC BIO INCIVERIC BIO INC | 85,230 | $1.53M | shares |
| LEAP THERAPEUTICS INCLEAP THERAPEUTICS INC | 1,066,689 | $939K | shares |
| IKENA ONCOLOGY INCIKENA ONCOLOGY INC | 220,082 | $781K | shares |
| LONGVIEW ACQUISITION CORP IILONGVIEW ACQUISITION CORP II | 149,999 | $10K | shares |
| ORION ACQUISITION CORPORION ACQUISITION CORP | 50,105 | $0 | shares |
How Q4 2022 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001343781-23-000001 | base | 2023-02-15 | acceptance time not in the bulk data set |